Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Onconetix (ONCO) Change in Accured Expenses (2023 - 2025)

Onconetix (ONCO) has disclosed Change in Accured Expenses for 2 consecutive years, with -$56269.0 as the latest value for Q4 2024.

  • On a quarterly basis, Change in Accured Expenses fell 261.71% to -$56269.0 in Q4 2024 year-over-year; TTM through Dec 2024 was -$1.1 million, a 19.85% decrease, with the full-year FY2024 number at -$1.1 million, down 19.85% from a year prior.
  • Change in Accured Expenses was -$56269.0 for Q4 2024 at Onconetix, up from -$179553.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $34796.0 in Q4 2023 to a low of -$775008.0 in Q2 2023.